Presentation is loading. Please wait.

Presentation is loading. Please wait.

Figure 1 NIR fluorescence is more suitable for

Published byRosalinda Natali Modified over 6 years ago

Similar presentations

Presentation on theme: "Figure 1 NIR fluorescence is more suitable for"— Presentation transcript:

1 Figure 1 NIR fluorescence is more suitable for
in vivo imaging applications than visible-light fluorescence Figure 1 | NIR fluorescence is more suitable for in vivo imaging applications than visible-light fluorescence. Near-infrared (NIR) fluorophores (700–900 nm) have deeper tissue penetration and lower background fluorescence than visible-light fluorescence, resulting in enhanced signal-to-noise ratios. The detection depths achievable with the currently available instrumentation ranges from millimeters with NIR fluorescence to micrometers with visible-range fluorescence. Zhang, R. R. et al. (2017) Beyond the margins: real-time detection of cancer using targeted fluorophores Nat. Rev. Clin. Oncol. doi: /nrclinonc

Download ppt "Figure 1 NIR fluorescence is more suitable for"

Similar presentations

Epifluorescence Confocal. Zoom 1 Zoom 2 Zoom 4.

Epifluorescence Confocal. Zoom 1 Zoom 2 Zoom 4.
Sergey Kucheryavski Raman spectroscopy Acquisition, preprocessing and analysis of spectra.

Sergey Kucheryavski Raman spectroscopy Acquisition, preprocessing and analysis of spectra.
Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,

Figure 1 Food, nutrition, obesity, physical activity, and the cellular processes linked to cancer Figure 1 | Food, nutrition, obesity, physical activity,
Figure 1 Estimated annual percentages of new

Figure 1 Estimated annual percentages of new
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.

Figure 2 Underreporting by physicians of specific treatment-associated symptoms by physicians in the TORCH trial Figure 2 | Underreporting by physicians.
Figure 3 Response after appearance of a new lesion

Figure 3 Response after appearance of a new lesion
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 1 Concept of the therapeutic index

Figure 1 Concept of the therapeutic index
Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.

Figure 4 Example of PK/PD simulation to optimize a vinorelbine treatment regimen Figure 4 | Example of PK/PD simulation to optimize a vinorelbine treatment.
Figure 2 Multiscale modelling in oncology

Figure 2 Multiscale modelling in oncology
Figure 5 Schematic illustration of different clinical trial designs

Figure 5 Schematic illustration of different clinical trial designs
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Multispectral Endoscopic Imaging of Colorectal Dysplasia In Vivo

Multispectral Endoscopic Imaging of Colorectal Dysplasia In Vivo
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Nat. Rev. Clin. Oncol. doi: /nrclinonc

Nat. Rev. Clin. Oncol. doi: /nrclinonc
Figure 2 Copy-number variations in multiple myeloma

Figure 2 Copy-number variations in multiple myeloma

Similar presentations

Ads by Google